TABLE 1.
Univariate and multivariate analyses of RFS and OS with IGKC expression and clinicopathological characteristics in ESCC patients
| Univariate | Multivariate | |||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p Value a | HR | 95% CI | p Value a | |||
| RFS | ||||||||
| Sex | ||||||||
| Female | 1 (Ref) | 1 (Ref) | ||||||
| Male | 1.1 | 0.51‐2.5 | .76 | 1.1 | 0.50‐2.5 | .78 | ||
| Age | ||||||||
| <65 b | 1 (Ref) | 1 (Ref) | ||||||
| ≥65 | 1.1 | 0.66‐1.9 | .70 | 1.4 | 0.82‐2.4 | .22 | ||
| T stage c | ||||||||
| T1, 2 | 1 (Ref) | 1 (Ref) | ||||||
| T3, 4 | 2.5 | 1.5‐4.2 | .0007 | 2.0 | 1.2‐3.5 | .013 | ||
| Lymph node metastasis | ||||||||
| Negative | 1 (Ref) | 1 (Ref) | ||||||
| Positive | 3.2 | 1.7‐5.9 | .0003 | 2.5 | 1.3‐4.8 | .0058 | ||
| IGKC expression | ||||||||
| Low | 1 (Ref) | 1 (Ref) | ||||||
| High | 0.25 | 0.13‐0.48 | <.0001 | 0.23 | 0.12‐0.45 | <.0001 | ||
| OS | ||||||||
| Sex | ||||||||
| Female | 1 (Ref) | 1 (Ref) | ||||||
| Male | 1.1 | 0.38‐3.0 | .90 | 0.93 | 0.32‐2.7 | .89 | ||
| Age | ||||||||
| <65 b | 1 (Ref) | 1 (Ref) | ||||||
| ≥65 | 1.2 | 0.63‐2.4 | .55 | 1.7 | 0.88‐3.5 | .11 | ||
| T stage c | ||||||||
| T1, 2 | 1 (Ref) | 1 (Ref) | ||||||
| T3, 4 | 2.6 | 1.4‐5.1 | .0044 | 2.3 | 1.1‐4.7 | .021 | ||
| Lymph node metastasis | ||||||||
| Negative | 1 (Ref) | 1 (Ref) | ||||||
| Positive | 3.1 | 1.4‐6.8 | .0052 | 2.3 | 1.02‐5.2 | .049 | ||
| IGKC expression | ||||||||
| High | 1 (Ref) | 1 (Ref) | ||||||
| Low | 0.22 | 0.097‐0.51 | .0004 | 0.20 | 0.086‐0.47 | .0002 | ||
a
Cox regression analysis.
b
Mean age.
c
According to the Union for International Cancer Control (UICC) staging system.
RFS, recurrence‐free survival; OS, overall survival; nNACT, treated without neoadjuvant chemotherapy; NACT, treated with neoadjuvant chemotherapy; HR, hazard ratio; CI, confidence interval; IGKC, immunoglobulin κ C; bold; Significant p values.